Biohaven Ltd. (NYSE:BHVN) Director John W. Childs Buys 32,700 Shares

Biohaven Ltd. (NYSE:BHVN) Director John W. Childs purchased 32,700 shares of the business’s stock in a transaction that occurred on Tuesday, March 4th. The shares were bought at an average price of $30.47 per share, for a total transaction of $996,369.00. Following the completion of the purchase, the director now directly owns 2,320,571 shares in the company, valued at $70,707,798.37. This represents a 1.43 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Biohaven Trading Down 1.2 %

Shares of BHVN opened at $30.98 on Thursday. The firm has a market capitalization of $3.13 billion, a PE ratio of -3.31 and a beta of 1.27. The stock’s 50 day moving average is $38.07 and its two-hundred day moving average is $42.66. Biohaven Ltd. has a twelve month low of $26.80 and a twelve month high of $62.21.

Biohaven (NYSE:BHVN) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($1.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.29). On average, sell-side analysts predict that Biohaven Ltd. will post -8.9 EPS for the current year.

Hedge Funds Weigh In On Biohaven

Large investors have recently made changes to their positions in the stock. Spire Wealth Management purchased a new position in Biohaven in the 4th quarter valued at approximately $56,000. US Bancorp DE grew its holdings in Biohaven by 57.1% in the third quarter. US Bancorp DE now owns 2,173 shares of the company’s stock valued at $109,000 after purchasing an additional 790 shares during the last quarter. Amalgamated Bank increased its position in shares of Biohaven by 21.9% in the fourth quarter. Amalgamated Bank now owns 2,929 shares of the company’s stock valued at $109,000 after buying an additional 527 shares in the last quarter. KBC Group NV raised its stake in shares of Biohaven by 24.5% during the 3rd quarter. KBC Group NV now owns 2,250 shares of the company’s stock worth $112,000 after buying an additional 443 shares during the last quarter. Finally, Quarry LP purchased a new stake in shares of Biohaven in the fourth quarter valued at about $112,000. Hedge funds and other institutional investors own 88.78% of the company’s stock.

Analysts Set New Price Targets

BHVN has been the topic of several research reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $61.00 price objective on shares of Biohaven in a report on Tuesday. TD Cowen lifted their price target on Biohaven from $55.00 to $75.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Deutsche Bank Aktiengesellschaft initiated coverage on Biohaven in a report on Tuesday, February 11th. They issued a “buy” rating and a $65.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating on shares of Biohaven in a research report on Tuesday, December 17th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Biohaven from $72.00 to $68.00 and set an “overweight” rating for the company in a research report on Wednesday. Fourteen analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $62.77.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.